CoChat
Sign Up
Cited by 162Cardiac Ischemia and ReperfusionAcute Myocardial Infarction ResearchCoronary Interventions and Diagnostics

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

EMBRACE STEMI study: a Phase 2a trial to evaluate the safety, tolerability, and efficacy of intravenous MTP-131 on reperfusion injury in patients undergoing primary percutaneous coronary intervention

Gibson, C. Michael, Giugliano, Robert P., Kloner, Robert A., Bode, Christoph, Tendera, Michal, Jánosi, András, Merkely, Bela, Godlewski, Jacek, Halaby, Rim, Korjian, Serge, Daaboul, Yazan, Chakrabarti, Anjan K., Spielman, Kathryn, Neal, Brandon J., Weaver, W. Douglas·2016·European Heart Journal
DOI 10.1093/eurheartj/ehv597
Open this paper in CoChat — free account

Abstract

AIMS: Among patients with ST-elevation myocardial infarction (STEMI), reperfusion injury contributes to additional myocardial damage. MTP-131 is a cell-permeable peptide that preserves the integrity of cardiolipin, enhances mitochondrial energetics, and improves myocyte survival during reperfusion. METHODS AND RESULTS: EMBRACE STEMI is a multicentre, randomized, double-blind Phase 2a trial that evaluated the efficacy and safety of MTP-131 vs. placebo infused at a rate of 0.05 mg/kg/h for 1 h among first-time anterior STEMI subjects undergoing primary percutaneous coronary intervention (PCI) for a proximal or mid left anterior descending (LAD) artery occlusion. Administration of MTP-131 was not associated with a significant reduction in the primary endpoint, infarct size by creatine kinase-myocardial band (CK-MB) area under the curve (AUC) over 72 h (5785 ± 426 ng h/mL in placebo vs. 5570 ± 486 ng h/mL in MTP-131; ITALIC! P = NS). MTP-131 was not associated with an improvement in pre-specified magnetic resonance imaging, angiographic, electrocardiographic, or clinical outcomes. CONCLUSION: Among subjects with first-time anterior STEMI due to a proximal or mid LAD lesion who undergo successful PCI, administration of MTP-131 was safe and well tolerated. Treatment with MTP-131 was not associated with a decrease in myocardial infarct size as assessed by AUC0-72 of CK-MB.

Overview

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehv597

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Research works printed but not linked: 2

  1. 10.1056/NEJMoa071142 · DOI
  2. Atar, 2014, Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results, Eur Heart J, 36, 112, 10.1093/eurheartj/ehu331 · DOI

Cited by

Sorted by citations

See all 162

Related

Metadata

Authors
Gibson, C. M., Giugliano, R. P., Kloner, R. A., Bode, C., Tendera, M., Jánosi, A., Merkely, B., Godlewski, J., Halaby, R., Korjian, S., Daaboul, Y., Chakrabarti, A. K., Spielman, K., Neal, B. J., & Weaver, W. D.
Affiliations
  • Beth Israel Deaconess Medical Center (US)
  • Brigham and Women's Hospital (US)
  • University of Southern California (US)
  • University of Freiburg (DE)
  • Gottsegen National Cardiovascular Center (HU)
  • John Paul II Hospital (PL)
  • Harvard University (US)
  • Eastern Virginia Medical School (US)
  • Henry Ford Hospital (US)
Corresponding author
Gibson, C. Michael
ORCID
Venue
European Heart Journal
Publisher
Oxford University Press (OUP)
Published
2015-11-19
Volume
37
Issue
16
Pages
1296.1-1303
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
DOI
10.1093/eurheartj/ehv597
OpenAlex
W2176701303
Cited by
162
References
36
Citations by year
2026: 9 · 2025: 12 · 2024: 15 · 2023: 12 · 2022: 19 · 2021: 9 · 2020: 19 · 2019: 13 · 2018: 17 · 2017: 19 · 2016: 18
FWCI
14.28
Type
journal article
Language
en
Open access
closed
Locations
  • European Heart Journal (publishedVersion)
  • PubMed (publishedVersion)
  • HighWire Press Open Archive (submittedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Ischemia and Reperfusion
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
Keywords
ST-elevation myocardial infarction, ischemia-reperfusion injury, primary percutaneous coronary intervention, cell-permeable peptide, cardiolipin, mitochondrial bioenergetics, myocardial infarct size, CK-MB, left anterior descending artery occlusion, drug safety and tolerability
MeSH terms
ST Elevation Myocardial Infarction, Double-Blind Method, Humans, Oligopeptides, Percutaneous Coronary Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review